Venlafaxine & Desvenlafaxine

Venlafaxine — Effexor — was the first SNRI and is still the most prescribed. The clinical character of venlafaxine is shaped by two facts: it has a dose-dependent mechanism, and it has a short half-life. Both of those facts produce specific bedside consequences you need to anticipate.

The dose-dependent mechanism is the SNRI principle taken to its clearest expression. Below 150 milligrams a day, venlafaxine behaves like an SSRI — SERT inhibition is doing most of the work, and you'd be hard pressed to distinguish it from sertraline in terms of mechanism. Between 150 and 300 milligrams, NET inhibition becomes clinically meaningful and you have a true SNRI. Above 300 milligrams, modest dopamine reuptake inhibition appears, adding a third dimension. The patient who didn't respond to venlafaxine 75 milligrams may not have failed an SNRI trial — they may have failed an SSRI trial at moderate dose. Push to therapeutic SNRI dosing before declaring non-response.

The short half-life is the source of most of the practical headaches. Venlafaxine has a parent half-life of about five hours and an active metabolite (O-desmethylvenlafaxine, also marketed separately as desvenlafaxine) with a half-life of about eleven hours. That short tail produces severe discontinuation syndrome with missed doses. A patient who runs out of medication on a Friday afternoon and can't refill until Monday will likely be in significant discomfort by Saturday — flu-like sensations, dizziness, the characteristic "brain zaps," irritability, gastrointestinal symptoms.

Counsel patients about this at the first prescription. Tell them what missed doses feel like. Give them a strategy for what to do if they miss one. Plan ahead for travel, surgeries, anything that might interrupt access. The discontinuation syndrome is the single most common reason patients abandon venlafaxine, and most of those abandonments could have been prevented with a conversation at the start.

For planned discontinuation, taper slowly. Standard recommendation is at least four to six weeks. Many patients need longer. The XR formulation tapers more smoothly than IR. Some clinicians bridge to fluoxetine — switch to long-half-life fluoxetine, then taper the fluoxetine — to avoid the worst of the withdrawal.

Blood pressure monitoring is non-negotiable at higher doses. Baseline BP before starting. Recheck at each dose escalation. Watch particularly above 150 milligrams, where the NET effect on peripheral noradrenergic tone becomes clinically meaningful. Uncontrolled hypertension is a relative contraindication at full SNRI doses.

Desvenlafaxine — Pristiq — is the active metabolite marketed as its own drug. It bypasses CYP2D6 metabolism, so it has fewer drug interactions and less inter-patient variability. The clinical profile is otherwise similar to venlafaxine. Cost has historically been higher; the comparative advantage is modest for most patients.

Venlafaxine is a useful drug, but it asks something of the patient and the clinician — adherence, BP monitoring, planning around the short half-life. Brief that conversation up front, and the drug does what it's supposed to do.